DiaMedica Therapeutics In... (DMAC)
DiaMedica Therapeutics Inc. (DMAC) Stock Price, Analysis & Data
| Precio de compra | n/a |
| Capitalización de mercado | 362.92M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | -37.54M |
| Beta | 0.97 |
| EPS (TTM) | -0.72 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -8.33 |
| P/B (TTM) | 9.47 |
| P/S (TTM) | n/a |
| Earnings Date | Nov 11, 2026 |
| Precio de venta | n/a |
| Volumen | 3,932 |
| Volumen medio (20D) | 200,787 |
| Abierto | 6.74 |
| Anterior Cerrar | 6.75 |
| Rango del día | 6.67 - 6.74 |
| Rango de 52 semanas | 5.14 - 10.42 |
| analista | Strong Buy |
| Precio objetivo | 13 (93.16%) |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de DMAC
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company...
Desempeño financiero
En 2025, los ingresos de DiaMedica Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -32.77M, un aumento de 34.05%.
Estados financierosPronóstico del analista
Según las calificaciones de los analistas de 4, la calificación promedio de las acciones de DMAC es "Strong Buy". El pronóstico del precio de las acciones a 12 meses es 13, que es Potencial alcista de 93.16% del último precio.
Previsiones bursátilesSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
1 semana hace · Insider Monkey
DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential1 Main Capital, a boutique investment firm, recently released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. 1 Main Capital Partners returned 15.0% in Q2 2026, c...